
    
      This is a single arm phase II study for subjects receiving first line therapy for metastatic
      squamous cell lung cancer. Following informed consent and eligibility check, all subjects
      will receive therapy with carboplatin and ABRAXANE on an outpatient basis. A total of 50
      subjects will be enrolled over an enrollment period of about 24 months. Interim analyses will
      be conducted after the enrollment of subject 15, subject 30, and subject 45. Tissue
      biomarkers will be analyzed at baseline; and blood biomarkers will be analyzed at baseline,
      pre-dose on cycles 3 and 5, and then within 30 days of last dose of study treatment.
    
  